A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin

Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features

(2010) Gianfranco Cervellin et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

(2009) J. M. Del Campo et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Rhabdomyolysis and Acute Kidney Injury

(2009) Xavier Bosch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rhabdomyolysis in Community Acquired Bacterial Sepsis – A Retrospective Cohort Study

(2009) Anita A. Kumar et al.   PLoS One

The syndrome of rhabdomyolysis: Complications and treatment

(2008) Yiannis S. Chatzizisis et al.   European Journal of Internal Medicine